Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of flagging, with a record $3.5bn raised in IPOs across western stock exchanges in the first half of 2018 At the half year point 2018 is shaping up to have the lowest spend on medical…
Report library
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
EvaluatePharma Orphan Drug Report 2018
Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…
ASCO: Skirmishes Break Out In The Great Lung Cancer Battle
Report Highlights For prescribers, at least, it is becoming ever more important to stay up to date with the numerous subgroups into which first-line NSCLC is being…
EP Vantage Pharma, Biotech and Medtech 2017 In Review
Report Highlights All major healthcare indices climbed in 2017, echoing wider stock market strength The $80bn spent on pharma & biotech acquisitions in 2017 makes…
EP Vantage 2018 Preview
Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.